Acute Coronary Syndromes Clinical Trial
— NET-SCAOfficial title:
First Prospective Observational Registry of the Lazio Regional Network for Acute Coronary Syndromes
The NET-SCA Registry has been designed to document and evaluate the clinical epidemiology and current management of Acute Coronary Syndromes in the Lazio Region of Italy.
Status | Recruiting |
Enrollment | 3000 |
Est. completion date | December 2018 |
Est. primary completion date | December 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - admission to CCU for ACS Exclusion Criteria: - ACS due to major extracardiac causes (i.e. traumatic) |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Italy | Ospedale GG Grassi | Ostia | Roma |
Italy | Ospedale "G.B. Grassi" | Rome | |
Italy | Ospedale "Madre Giuseppina Vannini" | Rome | |
Italy | Ospedale "S. Eugenio" | Rome | |
Italy | Ospedale "Sandro Pertini" | Rome | |
Italy | Ospedale FBF "Isola Tiberina" | Rome | |
Italy | Policlinico Casilino | Rome | |
Italy | San Filippo Neri Hospital | Rome |
Lead Sponsor | Collaborator |
---|---|
San Filippo Neri General Hospital | Associazione Nazionale Medici Cardiologi Ospedalieri |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total Mortality | 12 months | Yes | |
Secondary | Cardiovascular Mortality | 12 months | Yes | |
Secondary | New admissions of ACS | 12 months | Yes | |
Secondary | New admissions for heart failure | 12 months | Yes | |
Secondary | New admissions for coronary revascularization | 12 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02552407 -
Thrombectomy in ST Elevation Myocardial Infarction, an Individual Patient Meta-analysis
|
N/A | |
Completed |
NCT01398228 -
Clinical Pathways for the Management of Acute Coronary Syndromes - Phase 3,CPACS-3
|
N/A | |
Completed |
NCT01135667 -
Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI
|
Phase 4 | |
Recruiting |
NCT02592720 -
Cocktail Injection Improves Outcomes of FFR Guided PCI
|
Phase 4 | |
Completed |
NCT01641510 -
PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic Variants
|
Phase 3 | |
Completed |
NCT01743274 -
Does Optical Coherence Tomography Optimise Results of Stenting
|
N/A | |
Active, not recruiting |
NCT01433627 -
Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX
|
Phase 3 | |
Completed |
NCT01452282 -
Ankle-Brachial Index Estimating Cardiac Complications After Surgery
|
N/A | |
Recruiting |
NCT01418794 -
Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease
|
Phase 4 | |
Recruiting |
NCT01000701 -
Inflammation and Acute Coronary Syndromes
|
N/A | |
Terminated |
NCT01107899 -
Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes
|
Phase 1 | |
Completed |
NCT00494247 -
Endothelial Progenitor Cells-capture Stents in Acute Coronary Syndromes
|
Phase 4 | |
Terminated |
NCT00615719 -
Computed Tomographic Coronary Angiography for Acute Chest Pain Evaluation
|
N/A | |
Active, not recruiting |
NCT06089343 -
High-risk Features of Coronary Lesions in CTA and OCT
|
||
Not yet recruiting |
NCT04023630 -
DUAL Antithrombotic Therapy in Patients With AF and ACS
|
Phase 4 | |
Recruiting |
NCT02601404 -
REal World Advanced Experience of BioResorbable ScaffolD by SMart Angioplasty Research Team (SMART REWARD)
|
N/A | |
Completed |
NCT02195193 -
Integrating Depression Care in Acute Coronary Syndromes Care in China
|
N/A | |
Not yet recruiting |
NCT01735227 -
Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Trials(OPEN)
|
Phase 4 | |
Completed |
NCT02141750 -
THIRD NATIONAL REGISTRY OF ACUTE CORONARY SYNDROMES
|
N/A | |
Completed |
NCT00097591 -
A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
|
Phase 3 |